TaiRx, Inc.

Industry · 8 registered clinical trials — 3 currently recruiting.

Status	Trial	Phase	Started
Recruiting	A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Comb HCC - Hepatocellular Carcinoma	Phase 2	2026-03-31
Recruiting	Study of TRX-920 for Patients With Advanced Solid Tumors Advanced Solid Tumor	Phase 1	2023-10-31
Recruiting	CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma, Advanced Cancer	Phase 2	2022-05-23
Completed	Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients Advanced Cancer	Phase 1	2020-05-25
Active Not Recruiting	Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor	Phase 2	2018-12-15
Terminated	CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma, Advanced Cancer	Phase 2	2018-07-12
Completed	Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients Carcinoma, Advanced Cancer	Phase 1	2016-03-25
Completed	A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Carcinoma, Advanced Cancer	Phase 1	2015-09-01